Cite
HARVARD Citation
Panayiotidis, P. et al. (2022). A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia. Leukemia & lymphoma. 63 (5), pp. 1058-1069. [Online].